Receptor activator of nuclear factor κB ligand and osteoprotegerin regulation of bone remodeling in health and disease
AE Kearns, S Khosla, PJ Kostenuik - Endocrine reviews, 2008 - academic.oup.com
Osteoclasts and osteoblasts dictate skeletal mass, structure, and strength via their respective
roles in resorbing and forming bone. Bone remodeling is a spatially coordinated lifelong …
roles in resorbing and forming bone. Bone remodeling is a spatially coordinated lifelong …
The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling
S Theoleyre, Y Wittrant, SK Tat, Y Fortun… - Cytokine & growth factor …, 2004 - Elsevier
The past decade has seen an explosion in the field of bone biology. The area of bone
biology over this period of time has been marked by a number of key discoveries that have …
biology over this period of time has been marked by a number of key discoveries that have …
Cancer-secreted hsa-miR-940 induces an osteoblastic phenotype in the bone metastatic microenvironment via targeting ARHGAP1 and FAM134A
K Hashimoto, H Ochi, S Sunamura… - Proceedings of the …, 2018 - National Acad Sciences
Bone metastatic lesions are classified as osteoblastic or osteolytic lesions. Prostate and
breast cancer patients frequently exhibit osteoblastic-type and osteolytic-type bone …
breast cancer patients frequently exhibit osteoblastic-type and osteolytic-type bone …
RANK–RANKL signalling in cancer
Oncogenic events combined with a favourable environment are the two main factors in the
oncological process. The tumour microenvironment is composed of a complex …
oncological process. The tumour microenvironment is composed of a complex …
Receptor activator of nuclear factor κB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss
Production of the cytokine receptor activator of NFκB ligand (RANKL) by lymphocytes has
been proposed as a mechanism by which sex steroid deficiency causes bone loss …
been proposed as a mechanism by which sex steroid deficiency causes bone loss …
The role of receptor activator of nuclear factor-κB (RANK)/RANK ligand/osteoprotegerin: clinical implications
D Vega, NM Maalouf, K Sakhaee - The Journal of Clinical …, 2007 - academic.oup.com
Context: Receptor activator of nuclear factor-κB ligand (RANKL), receptor activator of
nuclear factor-κB (RANK), and osteoprotegerin (OPG) play a central role in bone remodeling …
nuclear factor-κB (RANK), and osteoprotegerin (OPG) play a central role in bone remodeling …
Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL–RANK signaling system
S Tanaka, K Nakamura, N Takahasi… - Immunological …, 2005 - Wiley Online Library
Osteoclasts are primary cells for physiological and pathological bone resorption, and
receptor activator of nuclear factor‐κB ligand (RANKL) is critically involved in the …
receptor activator of nuclear factor‐κB ligand (RANKL) is critically involved in the …
Osteoclast signal transduction during bone metastasis formation
Osteoclasts are myeloid lineage-derived bone-resorbing cells of hematopoietic origin. They
differentiate from myeloid precursors through a complex regulation process where the …
differentiate from myeloid precursors through a complex regulation process where the …
Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation
G Chen, K Sircar, A Aprikian, A Potti, D Goltzman… - Cancer, 2006 - Wiley Online Library
BACKGROUND Late‐stage prostate cancer patients are refractory to hormone therapy and
exhibit a high propensity to develop skeletal metastasis. In this regard, the role of a novel …
exhibit a high propensity to develop skeletal metastasis. In this regard, the role of a novel …
Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma
Osteolytic bone disease in multiple myeloma (MM) is caused by enhanced osteoclast (OCL)
activation and inhibition of osteoblast function. Lenalidomide and bortezomib have shown …
activation and inhibition of osteoblast function. Lenalidomide and bortezomib have shown …